Anti-Mouse CD30/TNFRSF8 Rabbit Recombinant Antibody Proteintech 98209-1-RR

$299.00
In stock
SKU
98209-1-RR

 

241710B4, CD30, CD30L receptor, Lymphocyte activation antigen CD30, Tnfrsf8

Formulation::PBS, Azide Formulation::PBS, Azide1
Applications:Flow Cytometry (FC) Formulation::PBS, Azide2
 Reactivity:Rabbit / IgG Formulation::PBS, Azide3
Type:CatNo: Eg1307 Product name: Recombinant Mouse CD30/TNFRSF8 protein (His Tag) Source: mammalian cells-derived, pHZ-KIsec-C-6*HIS Tag: C-6*HIS Domain: 19-281 aa of NM_009401.2 Sequence: FPTDRPLKTTCAGDLSHYPGEAARNCCYQCPSGLSPTQPCPRGPAHCRKQCAPDYYVNEDGKCTACVTCLPGLVEKAPCSGNSPRICECQPGMHCCTPAVNSCARCKLHCSGEEVVKSPGTAKKDTICELPSSGSGPNCSNPGDRKTLTSHATPQAMPTLESPANDSARSLLPMRVTNLVQEDATELVKVPESSSSKAREPSPDPGNAEKNMTLELPSPGTLPDISTSENSKEPASTASTLSLVVDAWTSSRMQPTSPLSTGT Predict reactive species Formulation::PBS, Azide4
RRID:21941 Formulation::PBS, Azide5
Storage Buffer:Q60846 Formulation::PBS, Azide6
Background Information:CD30, also known as TNFRSF8 or Ki-1, is a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. It is composed of an extracellular domain with six cysteine-rich repeats, a transmembrane segment, and an intracellular domain (PMID: 1310894). CD30 is expressed on a small subset of activated T and B lymphocytes, and a variety of lymphoid neoplasms, with the highest expression in classical Hodgkin's lymphoma and anaplastic large cell lymphoma (PMID: 9826579; 28885612). The CD30 ligand (CD30L or CD153) is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily (PMID: 8701986). Signal transduction of CD30/CD30L utilizes signal transducers, TNFR-associated factors (TRAF1, 2, 3 and 5) (PMID: 9826579). Formulation::PBS, Azide7
biogegep8 Formulation::PBS, Azide8
biogegep9 Formulation::PBS, Azide9
Formulation::PBS, Azide0 Applications:Flow Cytometry (FC)0

 

 

Reviews

Write Your Own Review
You're reviewing:Anti-Mouse CD30/TNFRSF8 Rabbit Recombinant Antibody Proteintech 98209-1-RR
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.